Previous close | 24.13 |
Open | 25.05 |
Bid | 24.40 x 300 |
Ask | 24.46 x 100 |
Day's range | 24.13 - 25.24 |
52-week range | 20.67 - 41.36 |
Volume | |
Avg. volume | 1,279,791 |
Market cap | 3.028B |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Key Insights Significantly high institutional ownership implies Arrowhead Pharmaceuticals' stock price is sensitive to...
James Hamilton, Chief Discovery and Translational Medicine Officer at Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), sold 6,000 shares of the company on April 1, 2024, according to a recent SEC filing.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Myszkowski sold 40,000 shares of the company's stock on March 6, 2024, according to a recent SEC filing.